{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=docetaxel&page=50", "query": { "intervention": "docetaxel", "page": 50 }, "page_size": 10 }, "pagination": { "page": 50, "page_size": 10, "total_count": 1321, "total_pages": 133, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=docetaxel&page=51&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=docetaxel&page=49&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-31T06:57:29.558Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07291037", "title": "Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-small Cell Lung Cancer (NSCLC)" ], "interventions": [ { "name": "Datopotamab deruxtecan (Dato-DXd)", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 400, "start_date": "2025-10-31", "completion_date": "2029-01-29", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-31T06:57:29.558Z", "location_count": 51, "location_summary": "Chandler, Arizona • Gilbert, Arizona • Goodyear, Arizona + 47 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07291037" }, { "nct_id": "NCT01012297", "title": "Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Recurrent Uterine Corpus Sarcoma", "Stage IIIA Uterine Sarcoma", "Stage IIIB Uterine Sarcoma", "Stage IIIC Uterine Sarcoma", "Stage IVA Uterine Sarcoma", "Stage IVB Uterine Sarcoma", "Uterine Corpus Leiomyosarcoma" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Filgrastim", "type": "BIOLOGICAL" }, { "name": "Gemcitabine Hydrochloride", "type": "DRUG" }, { "name": "Pegfilgrastim", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 107, "start_date": "2009-11", "completion_date": "2015-09", "has_results": true, "last_update_posted_date": "2026-06-24", "last_synced_at": "2026-10-31T06:57:29.558Z", "location_count": 201, "location_summary": "Phoenix, Arizona • Burbank, California • Concord, California + 138 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Burbank", "state": "California" }, { "city": "Concord", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01012297" }, { "nct_id": "NCT00258362", "title": "Carboplatin, Docetaxel, and Radiation Therapy in Treating Patients With Stage III/IV, or Recurrent Endometrial Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Endometrial Cancer" ], "interventions": [ { "name": "carboplatin", "type": "DRUG" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 41, "start_date": "2005-07", "completion_date": "2009-12", "has_results": true, "last_update_posted_date": "2017-12-28", "last_synced_at": "2026-10-31T06:57:29.558Z", "location_count": 2, "location_summary": "Minneapolis, Minnesota • Saint Louis Park, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Saint Louis Park", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00258362" }, { "nct_id": "NCT04310007", "title": "Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Lung Non-Squamous Non-Small Cell Carcinoma", "Recurrent Lung Non-Squamous Non-Small Cell Carcinoma", "Stage IV Lung Cancer AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Cabozantinib S-malate", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Gemcitabine Hydrochloride", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Ramucirumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 117, "start_date": "2020-07-13", "completion_date": "2027-03-31", "has_results": false, "last_update_posted_date": "2026-10-26", "last_synced_at": "2026-10-31T06:57:29.558Z", "location_count": 611, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 392 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT04310007" }, { "nct_id": "NCT07365995", "title": "A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Castration-resistant Prostate Cancer" ], "interventions": [ { "name": "BNT324", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Prednisone/prednisolone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BioNTech SE", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 736, "start_date": "2026-04-22", "completion_date": "2031-02", "has_results": false, "last_update_posted_date": "2026-10-16", "last_synced_at": "2026-10-31T06:57:29.558Z", "location_count": 21, "location_summary": "Santa Barbara, California • Aurora, Colorado • Fort Myers, Florida + 17 more", "locations": [ { "city": "Santa Barbara", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "West Palm Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07365995" }, { "nct_id": "NCT00504257", "title": "Avastin in Combination With Docetaxel in Ovarian/Fallopian Tube/Peritoneum Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Fallopian Tube Cancer", "Ovarian Cancer", "Malignant Tumor of Peritoneum" ], "interventions": [ { "name": "Avastin", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 45, "start_date": "2007-03", "completion_date": "2012-10", "has_results": true, "last_update_posted_date": "2014-02-06", "last_synced_at": "2026-10-31T06:57:29.558Z", "location_count": 4, "location_summary": "Fort Lauderdale, Florida • St. Petersburg, Florida • Tampa, Florida + 1 more", "locations": [ { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00504257" }, { "nct_id": "NCT01673867", "title": "Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-Squamous Cell Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 582, "start_date": "2012-11-02", "completion_date": "2021-12-17", "has_results": true, "last_update_posted_date": "2023-02-08", "last_synced_at": "2026-10-31T06:57:29.558Z", "location_count": 30, "location_summary": "Scottsdale, Arizona • Duarte, California • San Diego, California + 23 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT01673867" }, { "nct_id": "NCT01193257", "title": "Study Comparing Orteronel Plus Prednisone in Participants With Metastatic Castration-Resistant Prostate Cancer.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Orteronel", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Orteronel Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Millennium Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 1099, "start_date": "2010-11-15", "completion_date": "2016-02-29", "has_results": true, "last_update_posted_date": "2018-12-19", "last_synced_at": "2026-10-31T06:57:29.558Z", "location_count": 37, "location_summary": "Anchorage, Alaska • Fort Smith, Arkansas • Fountain Valley, California + 33 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Riverside", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01193257" }, { "nct_id": "NCT05132075", "title": "Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "JDQ443", "type": "DRUG" }, { "name": "docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 95, "start_date": "2022-06-15", "completion_date": "2026-10-03", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-31T06:57:29.558Z", "location_count": 1, "location_summary": "Renton, Washington", "locations": [ { "city": "Renton", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT05132075" }, { "nct_id": "NCT06989112", "title": "DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Endometrial Cancer" ], "interventions": [ { "name": "Trastuzumab deruxtecan", "type": "DRUG" }, { "name": "Rilvegostomig", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 600, "start_date": "2025-03-27", "completion_date": "2031-02-19", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-31T06:57:29.558Z", "location_count": 62, "location_summary": "Tucson, Arizona • Little Rock, Arkansas • Duarte, California + 56 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06989112" } ] }